Print this page
Friday, 05 February 2021 20:47

Anticoagulation news items. Week commencing 1st February 2021

DOAC Dipstick for detecting direct oral anticoagulants - Medtech innovation briefing [MIB248]

National Institute for Health and Care Excellence
This briefing describes the DOASENSE DOAC Dipstick, which is used for detecting direct oral anticoagulants (DOACs) in urine. A summary of the main relevant evidence is presented along with uncertainties in the evidence, the technology's potential place in therapy and its cost.

 

Rivaroxaban approved for use in EU (and UK) for treatment, and prevention of recurrence of venous thromboembolism

PharmaTimes
It will be licensed for treatment and prevention of venous thromboembolism recurrence in children from birth to below 18 years old, at least five days after initial parenteral anticoagulation treatment.

 

Management of Antithrombotic Therapy after Acute Coronary Syndromes

New England Journal of Medicine
This review article notes antithrombotic therapy is a central component of treatment after acute coronary syndromes; however, balancing the benefit with the bleeding risk is still controversial. Clinical research and recommended approaches to management are reviewed.

 

 

The above records have been identified by UKMi and feature in the NICE Medicines Awareness Service. Further details on this service can be found at:

http://www.evidence.nhs.uk/about-evidence-services/content-and-sources/medicines-information/new-medicines-awareness-services